Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges

The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depo...

Descripción completa

Detalles Bibliográficos
Autores principales: Arunogiri, Shalini, Lintzeris, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711199/
https://www.ncbi.nlm.nih.gov/pubmed/33303254
http://dx.doi.org/10.1016/j.jsat.2020.108221
Descripción
Sumario:The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.

Ejemplares similares